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Abstract: Extracellular vesicles (EVs) play an important role in cell-to-cell communication by
delivering coding and non-coding RNA species and proteins to target cells. Recently, the therapeutic
potential of EVs has been shown to extend to the field of solid organ transplantations. Mesenchymal
stromal cell-derived EVs (MSC-EVs) in particular have been proposed as a new tool to improve
graft survival, thanks to the modulation of tolerance toward the graft, and to their anti-fibrotic and
pro-angiogenic effects. Moreover, MSC-EVs may reduce ischemia reperfusion injury, improving the
recovery from acute damage. In addition, EVs currently considered helpful tools for preserving
donor organs when administered before transplant in the context of hypothermic or normothermic
perfusion machines. The addition of EVs to the perfusion solution, recently proposed for kidney, lung,
and liver grafts, resulted in the amelioration of donor organ viability and functionality. EVs may
therefore be of therapeutic interest in different aspects of the transplantation process for increasing
the number of available organs and improving their long-term survival.
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1. Introduction
Solid organ transplantation represents the gold standard treatment for patients with end-stage
organ failure. Specifically, kidney transplantation has become a routine procedure because of its
beneficial effects on patient survival and quality of life, together with its economic aspects [1]. Although
the global observatory on donation and transplantation reported a total of 139,024 solid organ
transplants worldwide with 90,306 kidneys in 2017, this met less than 10% of the global need [2]. Data
from Eurotransplant [3], NHS-UK [4], and US registries [5] show that 141,568 patients are waiting
for a transplant, 82% of which are kidney transplants. Therefore, the gap existing between the need
for transplants and organ availability represents a major challenge to be addressed by scientific
community [6]. To reduce this gap, novel strategies have to be explored. The main option being
explored at present is the increase of the pool of deceased donors, including donors after circulatory
death (DCDs), which actually represent about 20% of the deceased donors worldwide, and older donors
with comorbidities such as hypertension, mild renal impairment, and death from cerebrovascular
events (extended criteria donors, ECDs) [7]. Nevertheless, organs from DCDs and ECDs are more prone
to developing an ischemic-reperfusion injury (IRI) compared to standard donors, and consequently
represent an increased risk of primary non-function and delayed graft function (DGF) [8]. In addition,
long-term graft survival is still a critical factor that needs to be improved.
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Among the different strategies in regenerative medicine, EVs have been recently recognized as
a promising and innovative tool with which to accelerate tissue recovery after organ damage. EVs are
a heterogeneous group of membranous vesicles that possess a central role in the mechanisms of
cell-to-cell communication [9,10]. In the last decade, interest and knowledge in the field of EVs has
increased enormously, and it is now well established that EVs may influence the function of target cells
by transferring bioactive molecules and genetic materials, inducing epigenetic changes in recipient
cells [11–13].
In this review, we present the current literature regarding the potential application of stem-cell-derived
EVs, dissecting their possible application as an innovative therapeutic tool to precondition grafts before
transplant as well as to prevent ischemic/reperfusion damage (Figure 1). In particular, we describe their use
in pre-transplant solid organ preservation in association with normothermic and hypothermic perfusion
machines. In addition, their role in the limitation of IRI is highlighted for kidney, liver, lung, and heart.
Finally, we present their immunomodulatory properties in bone marrow transplantation.
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2. Stem-Cell-Derived EVs and Regenerative Medicine
EVs released by healthy cells are very heterogeneous in size and composition, and they can be
classified based on their origin and dimension into two main categories: small EVs, ranging between
30 and 100 nm, and large EVs, ranging between 50 and 1000 nm [14].
Among small EVs, exosomes are the most characterized vesicles, considered to originate from
multivesicular bodies after their fusion with the cell membrane [15]. However, other subtypes of small
EVs different from the multivesicular-body-derived exosomes have been identified, for instance after
plasma membrane budding [14].
Large EVs, also called microvesicles/ectosomes, comprise different populations of vesicles originating
from the budding of the plasma membrane [16]. The different EV populations express common and
specific surface markers. For instance, tetraspanins such as CD9, CD81, and CD63 are mainly expressed
by small EVs [14]. In addition, small EVs are characterized by the presence of molecules of the endosomal
sorting complex required for transport (ESCRT), heat shock proteins (HSP70 and HSP90), and auxiliary
proteins (ALIX, TSG101, and VPS4). In terms of variance, large EVs are specifically characterized by
expression of the CD40 ligand [17,18]. The detailed composition of EV cargo has been deeply dissected
and several databases collecting these results are now available, such as EVpedia [19], Exocarta [20],
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and Vesiclepedia [21]. EVs can be isolated from the majority of body fluids such as plasma and serum,
amniotic and seminal fluids, saliva, urine, or nasal and bronchial lavage fluids [9,22].
Is important to take into consideration that a limitation to consistent EV characterization is
the variability in EV isolation protocols. Depending on the size of EVs and on the fluids of origin,
different techniques can be utilized, including ultra-high-speed centrifugation, polymer precipitation,
immunoaffinity capture, or microfluidics-based techniques, among others [23]. Rigor criteria for EV
isolation and characterization were recently proposed by the International Society for Extracellular
Vesicles (ISEV) [14].
Stem-cell-derived EVs possess many characteristics in common with the originating cells;
for instance, they carry some transcription factors classically expressed by stem cells, such as Nanog
and Oct-4, as well as stem (CD133 and c-Kit) and mesenchymal markers (CD105, CD29, and CD73) [24].
It has been clearly demonstrated that stem-cell-derived EVs recapitulate the pro-regenerative capacity
of the cells of origin and, in particular, those derived from mesenchymal stromal cells (MSCs) appear
the ideal candidates to favor tissue regeneration. MSC-EVs may be isolated from MSCs derived from
different adult tissues such as bone marrow, peripheral and cord blood, adipose tissue, or neonatal
birth-associated tissues including placenta and umbilical cord [25]. Several studies have shown that
MSC-EVs possess strong pro-regenerative properties using preclinical models of renal, lung, liver, and
heart injuries, mimicking the beneficial effect of the cells themselves [14,26,27]. The activity of EVs
mainly results in the reduction of apoptosis, oxidative stress, and inflammation and in increase of cell
proliferation [24,28,29].
3. Normothermic and Hypothermic Perfusion Machines
In order to increase the number of successful transplants, the use of machine perfusion is currently
proposed to ameliorate the function of organs from marginal donors such as DCDs and ECDs. Dynamic
perfusion of organs appears a useful strategy to evaluate pretransplant graft function, limiting the
discard rate [30–32]. Moreover, this approach reduces the incidence of DGF in recipients receiving
organs from ECDs and DCDs.
At present, dynamic machine perfusion can be done in hypothermic (HMP) or in normothermic
(NMP) conditions with or without oxygen. Several studies have demonstrated that both HPM and NPM
are useful in the assessment of organ viability prior to transplantation [32–34]. Specifically, HMP is able
to reduce DGF and to increase the graft survival of organs harvested from ECDs, but conflicting results
have been reported on the beneficial effects of HMP on grafts from DCDs [35–40]. Another beneficial
effect of HMP is the removal of inflammatory mediators that may have detrimental effects on graft
function. The delivery of oxygen added to the hypothermic perfusate may help to restore adenosine
triphosphate (ATP) content [41–44]. Because of the unknown effects of this oxygenated perfusion on
transplanted patients, a large international randomized controlled trial has been planned to investigate
the beneficial effects of oxygenated short-term perfusion of kidneys from ECDs (Consortium for Organ
Preservation in Europe COPE Trials) [45].
As oxygenated machine perfusion, NMP may protect organs from IRI by restoring ATP levels [46,47].
In particular, ex vivo normothermic perfusion, consisting of circulation through the harvested organs of
warm oxygenated red-cell-based solution, is able to restore the metabolism and function of the graft
prior to transplantation [48–50]. NMP could offer a better evaluation of organ viability compared to
HMP, especially in kidney and liver grafts because of urine or bile production, together with a better
preservation of graft function [51].
Both HMP and NMP allow the delivery of targeted therapies to organs prior to transplantation.
In particular, these approaches offer the potential to explore the effects of several therapeutic strategies,
such as gene-silencing, nanoparticles, and cell therapies, in a fully functioning graft [52–57].
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4. EVs for Kidney Transplant
An innovative EV-based application for organ preservation is the use of EVs in the perfusion
solution. A first report in the literature recently demonstrated that EVs released by MSCs, delivered in
the perfusate during organ cold perfusion (4 h), preserve and protect kidney function. Histological
and genetic analyses on EV-treated kidneys revealed upregulation of enzymes involved in energy
metabolism and reduction of global ischemic damage. In addition, the analysis of lactate, LDH,
and glucose in the effluent fluid confirmed a greater use of energy substrates by EV-treated kidneys,
supporting the report of improved functionality (Table 1) [58].
Moreover, an extensive number of publications have highlighted the beneficial effect of EVs
in preclinical models of IRI, further implying their possible application to limit organ damage [9].
In particular, EVs isolated from different MSC sources [59–62] have been shown to accelerate renal
recovery after damage, promoting cell proliferation and blocking inflammation and apoptosis when
intravenously injected after IR damage [63]. The mechanisms of action reported appear different
between the EV sources: MSC-EVs obtained from Wharton’s jelly stimulate tubular proliferation and
reduce inflammation and apoptosis via mitochondrial protection [61,62], while those from cord blood
promote tubular dedifferentiation and proliferation by the transfer of human HGF [60]. Moreover,
EVs isolated from bone marrow MSCs were protective mainly by suppressing inflammation when
injected under the renal capsule [64]. In addition, EVs obtained from MSCs isolated from glomeruli
have also been demonstrated to be capable of reducing ischemic damage [65].
Moreover, a recent publication demonstrated that EVs isolated from the venal perfusate of rats
subjected to remote ischemia preconditioning ameliorated renal function when injected into another
animal with IRI. To explore the underlying mechanism, authors tested in vivo, in the same IRI model,
the effect of EVs released by human proximal tubular cells cultured in hypoxia, supporting the thesis
that remote ischemia precondition activates a repairing program into tubular cells by the release of
pro-regenerative EVs [66].
Whereas all the studies mentioned above evaluated classical ischemic damage in models of
renal artery clamping, Wu and co-workers tested for the first time the effect of EVs in a rat model
of IRI after DCD renal transplantation [67]. The authors confirmed that Wharton’s jelly MSC-EVs,
intravenously injected after renal transplantation, mitigated renal damage, improving survival and
function. In particular, MSC-EVs were shown to reduce cell apoptosis and inflammation, to stimulate
HGF production, and subsequently to alleviate fibrosis [67].
Table 1. List of EV applications for organ preconditioning. Abbreviations: bone marrow (BM), human
liver stem cells (HLSCs).
Organs EV Sources Type ofPerfusion
Time of
Preconditioning Results References
Kidney BM-MSCs Hypothermic 4 h Preservation and protection Gregorini et al. [58]
Lung BM-MSCs Normothermic 6 h Improvement of ventilation andhemodynamic parameters Gennai et al. [68]
Lung BM-MSCs Normothermic 6 h Restoring permeability andreduction of inflammation Park et al. [69]
Lung BM-MSCs Normothermic 1 h Attenuation of IR dysfunction andimmunomodulation Stone et al. [70]
Lung BM-MSCs Normothermic 3 h Reduction of inflammation andoxidative stress Lonati et al. [71]
Liver HLSCs Normothermic 4 h Limitation of the progression ofischemic injury Rigo et al. [72]
5. EVs for Lung Transplantation
Adult lung transplantation is considered the most effective strategy for end-stage pulmonary
disease, although the reported 5-year survival rate is only 50% [73]. Infections, immunomodulation,
and IRI are in fact some of the aspects involved in lung transplant failure [74]. Through ex vivo lung
perfusion, donor lungs can be evaluated and reconditioned, while organs are perfused and ventilated [75].
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The use of MSC-EVs has been proposed as a valid alternative for the rehabilitation of marginal human
lungs [68]. Upon administering MSC-EVs in the perfusion fluid, a dose-dependent increase of alveolar
fluid clearance, a decrease of lung weight gain, and an improvement of airway and hemodynamic
parameters were observed as compared to perfusion alone (Table 2). Moreover, the study showed
that CD44 was involved in the EV uptake mechanism, as the efficacy of MSC-EVs decreased with the
administration of anti-CD44 antibody.
A significant improvement of inflammatory conditions has also been ascribed to the EV effect on
lung bacterial infections. For example, MSC-EVs have been demonstrated to be effective in restoring
lung protein permeability and reducing inflammation in Escherichia-coli-endotoxin-induced acute
lung injury in mice. In particular, MSC-EV treatment restored protein permeability and reduced
inflammation, extravascular lung water, and total protein levels in the bronchoalveolar lavage fluid,
demonstrating a reduction in pulmonary edema [76]. On this path, in a recent work, the effects of
MSC-EVs were investigated in an ex vivo perfused human lung model, injured with severe E. coli
pneumonia [69]. The paper confirmed a significant increase of alveolar fluid clearance and decrease
in protein permeability, as well as the lowering of the bacterial load and the neutrophil count in the
injured alveolus (Table 2). MSC pretreatment with a toll-like-receptor 3 agonist before the isolation of
EVs increased their bactericidal activity.
Moreover, Stone and colleagues demonstrated the attenuation of IR dysfunction in lungs after
treatment with MSC-EVs both in vivo and in ex vivo perfusion systems [70]. In particular, they observed
a decrease of pro-inflammatory cytokines and upregulation of keratinocyte growth factor, PGE2, and
IL-10. Recently, in a mouse model of ex vivo lung perfusion, EV-treated organs showed decreased
vascular resistance and a rise of perfusate nitric oxide metabolites. Moreover, EV treatment prevented
the reduction in pulmonary ATP and increased the medium–high-molecular-weight hyaluronan in
the perfusate. The genes modulated in the pulmonary tissue by EV administration were involved in
anti-inflammatory and anti-oxidative stress pathways [71].
6. EVs for Liver Transplantation
The use of EVs released by stem cells as an innovative option to improve the viability of
pre-transplant livers was recently assessed in a model of ex vivo rat liver NMP. HLSC-EVs (EVs
isolated from human liver stem cells) were added to perfusate 15 min after the initiation of NMP and
administered for 4 h within the perfusate. The results showed that HLSC-EVs limited the progression
of ischemic injury, with a significant reduction of the levels of aspartate aminotransferase and alanine
aminotransferase and a decrease of histological damage compared with results of NMP alone (Table
2) [72]. Moreover, the authors demonstrated that HLSC-EVs were uptaken by hepatocytes, supporting
the thesis that EVs may recondition liver cells before transplantation [72].
Moreover, the potential therapeutic use of stem-cell-derived-EVs for liver regeneration, has been
also clearly demonstrated in pre-clinical models of liver IRI. In fact, hepatic ischemia and related
inflammation should be limited to avoid complication after liver transplantation [77]. The intravenous
injection of murine MSC-EVs prior to IRI reduced the area of necrosis and apoptosis with concomitant
increased liver function [77]. In addition, MSC-EVs have been shown to limit liver inflammation and
oxidative stress [77]. Similar results were obtained using EVs isolated from MSCs from inducible
pluripotent stem cells [78] or bone marrow [79]. Recently, Yao et al. demonstrated that human umbilical
cord MSC-EVs protect hepatic apoptosis post-IRI, modulating neutrophils and reducing oxidative
stress [80].
7. Stem-Cell-Derived EVs as Future Therapeutics in Heart Transplantation
EVs have been shown to be powerful allies against cardiovascular damage. Some important
interconnected effects related to EVs could improve the success of a heart transplantation, including
immunomodulatory properties, the improvement of heart function and vessel formation, and the
amelioration of myocardial function during IRI [81].
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Much evidence confirms the hypothesis that cardiac progenitor cells release pro-regenerative
and anti-fibrotic EVs in response to hypoxic conditions [82,83], mainly due to their miRNA cargo [82].
Moreover, cardiac-progenitor-cell-derived EVs, released into their environment, can stimulate migration
of endothelial cells [84] and inhibit both cardiac fibroblast activation and collagen synthesis [85].
In parallel, MSC-EV treatment has also been proven as a therapeutic option to limit ischemic
damage in the heart. In particular, MSC-EV administration increased phosphorylated-Akt and
phosphorylated-GSK-3β, as well as ATP/NADH level, and could reduce phosphorylated-c-JNK and
inflammatory response in ischemic/reperfused hearts [86].
8. EVs for Islet Transplantation
Today, there are still many factors that limit the success of pancreatic islet transplantation, including
islet source limitation, sub-optimal engraftment, lack of oxygen and blood supply for transplanted
islets, and immune rejection [87]. In parallel with the other described organs, MSC-EVs may also be of
benefit for islet transplantation.
One of the primary reasons for apoptosis and reduced beta-cell function in transplants is hypoxic
damage. Recently, EVs from human-umbilical-cord-derived MSCs were shown to have a therapeutic
effect on the survival and function of neonatal porcine islets exposed to hypoxia [88]. The use of EVs,
in comparison with medium alone, enhanced the yield and survival of porcine islets, and showed
an improvement of the function through the amelioration of mitochondrial respiration efficiency [88].
In addition, Di Wen and colleagues showed that MSC-EV administration through delivery of
small RNAs promoted islet function and inhibited immune rejection [89]. In a mouse model, they used
MSC-EVs transfected with shFas and anti-miR-375 in order to silence Fas and miR-375 in human
islets, observing an improvement of islet viability and function. Moreover, the authors observed the
inhibition of peripheral blood mononuclear cell proliferation and the enhancement of T-cell regulatory
function. Based on these works, EVs from different sources appear of interest to increase the possibility
of successful islet transplantation.
9. Role of MSC-EVs in the Amelioration of Graft Versus Host Disease
EVs derived from bone marrow MSCs possess an immunosuppressive potential that can be
harnessed to treat graft versus host disease (GVHD), which today represents the greatest complication
after allogeneic transplantation. The majority of the literature on the subject has generically focused on
the effects of the whole MSC secretome, including EVs and soluble factors. Recently, the specific role of
EVs has been highlighted, showing an effect on innate and adaptive immunity (Table 2).
For example, in 2005, Aggarwal and Pittenger highlighted that the secretome, released by MSCs,
be responsible for modulation of immune reaction, involved in GVHD [90]. In fact, if co-cultured with
purified subpopulations of immune cells, human MSCs were able to switch an inflammatory response
into a tolerant phenotype. In particular, MSCs induced mature dendritic cells type 1 and type 2 to
decrease TNF-α and to increase IL-10 secretion, respectively; they also induced T helper 1 lymphocytes
and natural killer cells to decrease interferon (IFN) γ secretion. In addition, they enhanced a regulatory
response, causing the T helper 2 cells to increase secretion of IL-4, increasing the proportion of regulatory
T cells and producing prostaglandin (PG) E2 [90].
Moreover, soluble factors released by MSCs, such as vascular endothelial growth factor and IL-6,
were shown to inhibit T-cell proliferation and to be involved in a partial inhibition of dendritic cell
differentiation [91]. Selmani et al. not only confirmed the role of the MSC secretome in modulating
innate immunity, but they also sustained its strong modulation of adaptive immunity [92]. Moreover,
they reported that the nonclassic HLA class I molecule HLA-G is responsible for the immunomodulatory
properties of MSCs [92].
In a recent work, it was shown that bone marrow MSC-EVs recapitulate the therapeutic effects of
the cells against acute GVHD [93]. A systemic infusion of MSC-EVs in mice with acute GVHD was
associated with the suppression of CD4+ and CD8+ T cells and with the preservation of circulating
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naive T cells, possibly due to the unique microRNA profiles of MSC-EVs. The analysis on microRNA
cargo in MSC-EVs identified that their target genes were involved in regulation of the cell cycle, T-cell
receptor signaling, and GVHD [93]. These findings suggest that MSC-EVs could be a new potential
therapeutic option to prevent GVHD, to be tested in future clinical trials.
Table 2. Immunomodulatory properties of MSC secretome/EVs.
Cell Types Actions Mechanisms Effector References
T lymphocytes
Decrease of TH1 secretion of
IFN-γ [91]
Increase of TH2 secretion of
IL-4 [91]
Increase of the proportion of
T-regs [91]
Suppression of T-naïve
differentiation [94]
Decrease in proliferation and
migration [94]
Decrease of CD4+CD8+ [94]
Constitutive production
of COX2 and PGE2
[91–93]
Secretion of TGF-β [91]
Secretion of soluble
HLA-G5 [93]
Secretome [91–93]
EVs [94]
S. Aggarwal et al. [91]
Z Selmani et al. [93]
S. Fujii et al. [94]
DC
Reversion of maturation of
DCs [92]
Decrease DC1 production of
TNF-α [91]
Increase DC2 production of
IL-10 [91]
Secretion of IL-6 [91] Secretome [91,92] S. Aggarwal et al. [91]F. Djouad et al. [92]
NK
Inhibition [91]
Alteration of secreted
cytokines [91]
Secretion of indoleamine
2,3-deoxygenase [91]
Secretion of PGE2 [91]
Secretion of TGF-β [91]
Secretome [91] S. Aggarwal et al. [91]
10. Conclusions
The organ demand is continuously increasing and there is a constant need to expand the pool of
donors. Increasing organ availability represents a major challenge in the field of transplantation.
Among the most recent innovative strategies, the use of EVs seems very promising. The application
of EVs in the perfusion solution, recently proposed for kidney, lung, and liver grafts, results in the
amelioration of donor organ viability and functionality. Moreover, consolidated results describe the
beneficial effects of EV administration in several preclinical models of IRI. In particular, stem-cell-derived
EVs have displayed strong pro-regenerative properties in different models of renal, lung, liver, and
heart injuries. IRI is an unavoidable consequence after transplants and the severity of this phenomenon
affects the graft outcome, leading to delayed graft function, graft rejection, chronic rejection, and chronic
graft dysfunction. The development of strategies to limit the progression of IRI is fundamental for the
success of transplants. Altogether, EVs appear the ideal candidate to target different aspects during
transplantation process.
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